Role of the Appropriateness of the Pelvic Lymphadenectomy and Adjuvant Radiation Therapy in Early-Stage Poorly Differentiated Endometrial Carcinoma

2018 ◽  
Vol 16 (4) ◽  
Author(s):  
Valerio Nardone ◽  
Paolo Tini ◽  
Luisa Marciello ◽  
Giuseppe Battaglia ◽  
Pierpaolo Pastina ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Endometrial Carcinoma ◽  
Early Stage ◽  
Pelvic Lymphadenectomy ◽  
Adjuvant Radiation ◽  
Adjuvant Radiation Therapy ◽  
Poorly Differentiated

Increased risk of recurrence in early-stage endometrial carcinoma after delays in adjuvant radiation treatment

2020 ◽  
Vol 31 (1) ◽  
pp. 73-77
Author(s):  
Simeng Zhu ◽  
Remonda Khalil ◽  
Osama Altairy ◽  
Charlotte Burmeister ◽  
Irina Dimitrova ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Endometrial Carcinoma ◽  
Radiation Treatment ◽  
Early Stage ◽  
Time Interval ◽  
Adjuvant Radiation ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Adjuvant Radiation Therapy ◽  
Disease Specific

ObjectiveThe benefits of adjuvant radiation treatment after hysterectomy have been confirmed in select patients with early-stage endometrial carcinoma. The goal of this study was to evaluate the prognostic impact of the time interval between hysterectomy and starting adjuvant radiation treatment in patients with early-stage endometrial carcinoma.MethodsOur database was searched for women with early-stage endometrioid endometrial cancer who received adjuvant radiation therapy after hysterectomy. The patients were classified into two groups based on the time interval to adjuvant radiation therapy (≤8 weeks or >8 weeks) after hysterectomy. Recurrence-free survival, disease-specific survival, and overall survival were compared between the two groups.ResultsFour hundred and sixty patients were identified. Median follow-up was 70.5 months (range 1–360). One hundred and seventy-six patients (38%) were 2009 International Federation of Gynecology and Obstetrics stage IA, 207 (45%) stage IB, and 77 (17%) stage II. Three hundred and fifty-four women (77%) received adjuvant radiation therapy within 8 weeks after hysterectomy. There was no statistically significant difference between the two groups in baseline demographics, disease and treatment characteristics, except for the modality of adjuvant radiation therapy. Patients who received adjuvant radiation therapy within 8 weeks experienced significantly less disease recurrence (9% vs 18%; p=0.01) and particularly less isolated vaginal recurrence (0% vs 6%, p=0.04). Five-year recurrence-free survival was 89% versus 80% (p=0.04), 5-year disease-specific survival was 93% for both groups, and 5-year overall survival was 86% versus 85% for patients who received adjuvant radiation therapy ≤8 and >8 weeks, respectively (p=0.88).ConclusionOur study suggests that delaying adjuvant radiation therapy beyond 8 weeks after hysterectomy is associated with significantly more cancer recurrences for women with early-stage endometrial carcinoma.

Esthesioneuroblastoma: the role of adjuvant radiation therapy

1993 ◽  
Vol 27 (4) ◽  
pp. 835-842 ◽  
Author(s):  
Robert L. Foote ◽  
Akio Morita ◽  
Michael J. Ebersold ◽  
Kerry D. Olsen ◽  
Jean E. Lewis ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Adjuvant Radiation ◽  
Adjuvant Radiation Therapy

Role of Adjuvant Radiation Therapy for Retroperitoneal Sarcomas: An 8-Institution Study from the US Sarcoma Collaborative

2019 ◽  
Vol 229 (4) ◽  
pp. S274
Author(s):  
Konstantinos Chouliaras ◽  
Kenneth Cardona ◽  
George A. Poultsides ◽  
Valerie P. Grignol ◽  
Callisia N. Clarke ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Adjuvant Radiation ◽  
Adjuvant Radiation Therapy ◽  
The Us ◽  
Retroperitoneal Sarcomas
Sign in / Sign up

Export Citation Format

Share Document